Freeline Therapeutics has developed a more robust test to detect the presence of neutralizing antibodies that affect the effectiveness of enzyme replacement therapy (ERT) or gene therapy in people with Fabry disease. The new test fulfills an unmet need for a standard, reliable positive sample (used as a positive control) that may help reduce current intra-lab test variability, supporting its validation as a robust, standardized test to characterize and monitor Fabry disease patients receiving ERT…

You must be logged in to read/download the full post.